We are one of the UK's fastest-growing companies that has been consistently recognised as one of the country's best places to work. For the last four years, it has been ranked in the Sunday Times' 100 Best UK companies to Work For list, coming 19th in 2005. The company is poised to break into the top ten companies on the back of sustained growth over a number of years.

Recently celebrating its 125th anniversary, the Bracknell-based company has a turnover of 150 million and more than 1000 employees. The purpose-built site includes nine divisions, from prescription medicines to IT and finance. One of the company's fastest growing products is its respiratory treatment Spiriva, comarketed with Pfizer. Painkiller Mobic and hypertension treatment Micardis Plus are two other top sellers in a portfolio spanning therapeutics areas, including respiratory, cardiology, cerebrovascular, CNS, virology & urology.

Its most important recent launches were those for duloxetine, the single molecule marketed for two separate indications:  Cymbalta/ Xeristar is a new entrant to the highly competitive anti- depressant market and Yentreve/Ariclain is the first ever treatment licenced for stress urinary incontinence. Both Products are co-marketed with Eli Lilly, and are tipped to be leading drugs in their fields.

Excellence in innovation and technology

Our production site in Bracknell UK is the centre for worldwide supply of Unit Dose Vials, which are produced using Blow Fill Seal technology. This type of manufacture, which is increasingly being used by the pharmaceutical industry, requires many specialist skills and expertise.